Treatment of Severe Atopic Dermatitis with Dupilumab in Three Patients with Renal Diseases

Background: Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease that can affect patients’ quality of life. Dupilumab is the first biologic agent approved for the treatment of patients with inadequately controlled moderate-to-severe AD and its mechanism of action is based on the i...

Descripción completa

Detalles Bibliográficos
Autores principales: Foti, Caterina, Romita, Paolo, Ambrogio, Francesca, Manno, Carlo, Filotico, Raffaele, Cassano, Nicoletta, Vena, Gino Antonio, De Marco, Aurora, Cazzato, Gerardo, Mennuni, Biagina Gisella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785101/
https://www.ncbi.nlm.nih.gov/pubmed/36556367
http://dx.doi.org/10.3390/life12122002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785101/
https://www.ncbi.nlm.nih.gov/pubmed/36556367
http://dx.doi.org/10.3390/life12122002

Ejemplares similares